Experience the power of KBI and Selexis in Geneva.
TO INTEGRATE, INNOVATE, REDUCE RISK, COLLABORATE
Fully-Integrated CDMO Services
Under one roof, KBI and Selexis provide services from cell line transfection through to cGMP drug manufacturing with Selexis’ specialized high-titer mammalian cell line development technologies and services and KBI’s cGMP bulk drug manufacturing for clinical and commercial requirements.
The fully integrated Selexis and KBI development platform has supported more than 60 clinical development programs with high productivity and robust product quality. The two companies have developed a seamless approach to optimize the client experience.
Experience best-in-class. Experience industry-leading. Experience it all in Geneva.
TO MANUFACTURE YOUR MOST COMPLEX MOLECULES
Best-in-class cell line development, process development, and manufacturing
KBI Biopharma and Selexis SA, both JSR Life Sciences companies, have launched an expanded, fully-integrated mammalian contract development and manufacturing services facility that is now open and operational in Geneva, Switzerland.
The ~94,000 square-foot integrated KBI/Selexis state-of-the-art facility builds upon the companies’ existing market foothold by combining best-in-class cell line development (CLD) and expert mammalian cell manufacturing in a single location. KBI and Selexis leverage their expertise and efficient end-to-end services for biomanufacturing clients.
This expansion enables industry-leading delivery of client programs through increased quality, efficiency, and time savings across a diverse portfolio of molecule formats.
To Get To First In Human, Faster
We have always been a science driven, customer centric company. This expansion in Geneva helps our clients optimize their complex biomanufacturing processes under accelerated timelines.
This facility expansion, together with our track record in the space, strengthens our commitment to deliver a seamless experience to the European biopharmaceutical community and clients around the globe.
This expansion in Geneva provides our global clients with streamlined capabilities to support mammalian-based therapies.
With a single touchpoint for best-in-class cell line development, process development, and manufacturing, clients experience heightened access to our process and product-based expertise.